Stage 1: At Risk
Primary Prevention
Early detection of metabolic predisposition without manifest complications. Focuses heavily on identifying risk factors before clinical symptoms appear.
Key Characteristics
- •Characterized by metabolic risk factors and early signs of adiposopathy
- •No clinically apparent complications yet present
- •Focus on primary prevention strategies
- •Regular monitoring and lifestyle interventions
- •Educational support for weight management
Key Biomarkers
- Fasting glucose
- Lipid profile
- Blood pressure
- Inflammatory markers
Clinical Interventions
- Lifestyle modifications
- Nutrition counseling
- Physical activity programs
- Risk factor monitoring
Stage 2: Mild/Moderate
Secondary Prevention
Presence of subclinical complications with early organ stress. Requires active secondary prevention to halt progression.
Key Characteristics
- •Evidence of metabolic dysfunction in one or more organ systems
- •Subclinical complications without significant functional impairment
- •Higher risk of disease progression
- •Intensive lifestyle and pharmacological interventions
- •Close monitoring for disease advancement
Key Biomarkers
- HOMA-IR
- Liver enzymes
- Microalbuminuria
- AHI index
Clinical Interventions
- GLP-1 agonists
- Metformin
- Intensive lifestyle programs
- Organ-specific monitoring
Stage 3: Established
Active Management
Manifest clinical complications requiring active disease management and a multidisciplinary care approach.
Key Characteristics
- •Clear evidence of clinical disease in multiple organ systems
- •Functional impairment and symptoms present
- •Requires comprehensive multidisciplinary approach
- •Aggressive pharmacological and lifestyle interventions
- •Regular clinical follow-up and adjustment
Key Biomarkers
- Type 2 Diabetes
- Sleep apnea
- Hypertension
- Coronary artery calcification
Clinical Interventions
- Combination pharmacotherapy
- Bariatric surgery consideration
- Specialized clinic services
- Behavioral therapy
Stage 4: Advanced
Tertiary Intervention
Structural damage and significant functional impairment from complications. Tertiary care is often required.
Key Characteristics
- •Severe complications with organ damage
- •Significant functional impairment and disability
- •Complex management requirements
- •Tertiary care involvement often necessary
- •Focus on preventing further deterioration
Key Biomarkers
- Heart failure
- CKD stage 3+
- Advanced cardiomyopathy
- End-organ damage
Clinical Interventions
- Advanced pharmacotherapy
- Cardiac/renal support
- Intensive medical management
- Surgical interventions
